Back to today’s briefing

Story perspectives

Study: Semaglutide Reduces Depression in Obese Patients

2/4/2025

40 9

Summary

Story summary

A recent analysis in JAMA Internal Medicine reveals promising news for patients with obesity: semaglutide 2.4 mg weekly does not heighten depressive symptoms or suicidal thoughts. Involving 3,377 participants, the study even noted a slight decrease in depression symptoms compared to a placebo, with psychiatric side effects remaining consistent across all groups.

1 of 1

Story summary

A recent analysis in JAMA Internal Medicine reveals promising news for patients with obesity: semaglutide 2.4 mg weekly does not heighten depressive symptoms or suicidal thoughts. Involving 3,377 participants, the study even noted a slight decrease in depression symptoms compared to a placebo, with psychiatric side effects remaining consistent across all groups.